Evidence map›Paper›PMID 25122524›Full record

ArticleNature protocols2014

Similarity-based modeling in large-scale prediction of drug-drug interactions.

Santiago Vilar, Eugenio Uriarte, Lourdes Santana, Tal Lorberbaum, George Hripcsak, Carol Friedman, Nicholas P Tatonetti

Abstract read
In one paragraph

Article in Nature protocols, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 277 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Adaptive Multi-Kernel Graph Neural Network for Drug-Drug Interaction Prediction.Interdisciplinary sciences, computational life sciences · 2025
    Article
  16. Review
  17. MFE-DDI: A multi-view feature encoding framework for drug-drug interaction prediction.Computational and structural biotechnology journal · 2025
    Article
  18. Article
  19. Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Santiago Vilar1] Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA. [2] Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Eugenio UriarteDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Lourdes SantanaDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.
Tal Lorberbaum1] Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA. [2] Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, New York, USA. [3] Department of Systems Biology, Columbia University Medical Center, New York, New York, USA.
George HripcsakDepartment of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.
Carol FriedmanDepartment of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.
Nicholas P Tatonetti1] Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA. [2] Department of Systems Biology, Columbia University Medical Center, New York, New York, USA. [3] Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Columbia University Irving Medical Center · USUniversidade de Santiago de Compostela · ES

Funding

Training in Cardiovascular Translational ResearchT32HL120826 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARKS, ANDREW ROBERT, TABAS, IRA A · 2014 to 2023
$4.7M
Pharmacovigilence using Natural Language Processing, Statistics, and the EHRR01LM010016 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRIEDMAN, CAROL · 2009 to 2016
$3.4M
Drug Effect Discovery Through Data Mining and Integrative Chemical BiologyR01GM107145 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TATONETTI, NICHOLAS P · 2014 to 2018
$2.5M
A Biomedical Natural Language Processing ResourceR01LM008635 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRIEDMAN, CAROL · 2005 to 2008
$2.1M
Training Program in Computational BiologyT32GM082797 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HONIG, BARRY H · 2008 to 2015
$1.4M
NHLBI NIH HHS T32 HL120826NHLBI NIH HHS T32HL120826NIGMS NIH HHS R01 GM107145NIGMS NIH HHS T32 GM082797NLM NIH HHS R01 LM008635NLM NIH HHS R01 LM010016NLM NIH HHS R01 LM010016-0S1NLM NIH HHS R01 LM010016-0S2
6 · The paper itself

Abstract

Drug-drug interactions (DDIs) are a major cause of adverse drug effects and a public health concern, as they increase hospital care expenses and reduce patients' quality of life. DDI detection is, therefore, an important objective in patient safety, one whose pursuit affects drug development and pharmacovigilance. In this article, we describe a protocol applicable on a large scale to predict novel DDIs based on similarity of drug interaction candidates to drugs involved in established DDIs. The method integrates a reference standard database of known DDIs with drug similarity information extracted from different sources, such as 2D and 3D molecular structure, interaction profile, target and side-effect similarities. The method is interpretable in that it generates drug interaction candidates that are traceable to pharmacological or clinical effects. We describe a protocol with applications in patient safety and preclinical toxicity screening. The time frame to implement this protocol is 5-7 h, with additional time potentially necessary, depending on the complexity of the reference standard DDI database and the similarity measures implemented.

Indexed as

Databases, PharmaceuticalModels, ChemicalArea Under CurveDrug InteractionsMolecular StructurePatient SafetyToxicity Tests

Identifiers

PMID25122524
PMCPMC4422192
OpenAlexW2091439417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.